Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy

@inproceedings{Taira2014MetforminIN,
  title={Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy},
  author={Al V. Taira and Gregory S. Merrick and Robert W. Galbreath and Mallory N Morris and Wayne M. Butler and Edward Adamovich},
  booktitle={Journal of contemporary brachytherapy},
  year={2014}
}
PURPOSE Several recent studies have suggested improved clinical outcomes in diabetic men with prostate cancer who also use metformin. We explore whether metformin use is associated with improved outcomes specifically in men undergoing prostate brachytherapy. MATERIAL AND METHODS 2,298 consecutive patients underwent permanent interstitial brachytherapy by a single brachytherapist (GSM). The cohort included 2028 non-diabetic men, 144 men with diabetes who were not taking metformin, and 126 men… CONTINUE READING